Literature DB >> 18507658

The reproducibility of adenosine monophosphate bronchial challenges in mild, steroid-naive asthmatics.

Dave Singh1, Jennifer Fairwood, Robert Murdoch, Amanda Weeks, Paul Russell, Kay Roy, Steve Langley, Ashley Woodcock.   

Abstract

AIMS: Repeated adenosine monophosphate (AMP) challenges are used to assess drug efficacy in clinical trials of mild, steroid-naive asthmatics. Refractoriness has been reported after repeated challenges over short intervals. This study evaluated possible tachyphylaxis after repeated AMP challenges at 12 and 24 h in mild, steroid-naive asthmatics.
METHODS: This was an open, three-way crossover study. Twenty-six steroid-naive asthmatic subjects were randomized to the following AMP challenge regimens separated by 7-14 days: (A) challenge at 08.00 h, repeated 24 h later; (B) challenge at 08.00 h, repeated 12 and 24 h later; (C) challenge at 20.00 h, repeated 12 h later. Comparisons within day were assessed using 90% confidence intervals (CIs). Non-inferiority approach taken with 1 doubling concentration (DC) as a clinically relevant difference.
RESULTS: Regimen A: Significant increase in AMP reactivity at 24 h. Mean DC difference was 0.6 (90% CI 0.24, 0.96). Regimen B: No evidence of difference between AMP reactivity at 08.00 h and a repeated challenge 12 h later. Repeated challenge at 24 h caused a significant increase in provocation concentration (PC)(20) compared with 12 h (mean DC difference 0.48, 90% CI 0.02, 0.95) and 0 h (mean DC difference 0.82, 90% CI 0.49, 1.14 - the upper CI exceeds the criteria of 1 DC). Challenge regimen C: No difference between challenges; mean DC difference of 0.28 (90% CI -0.2, 0.76).
CONCLUSION: The small decline in AMP reactivity during repeated challenges was not consistently observed, and was small compared with the known effects of inhaled drugs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18507658      PMCID: PMC2492916          DOI: 10.1111/j.1365-2125.2008.03186.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

Review 1.  Indirect bronchial hyper-responsiveness: the coming of age of a specific group of bronchial challenges.

Authors:  J Van Schoor; R Pauwels; G Joos
Journal:  Clin Exp Allergy       Date:  2005-03       Impact factor: 5.018

2.  Indirect airway challenges.

Authors:  G F Joos; B O'Connor; S D Anderson; F Chung; D W Cockcroft; B Dahlén; G DiMaria; A Foresi; F E Hargreave; S T Holgate; M Inman; J Lötvall; H Magnussen; R Polosa; D S Postma; J Riedler
Journal:  Eur Respir J       Date:  2003-06       Impact factor: 16.671

3.  Mometasone furoate antagonizes AMP-induced bronchoconstriction in patients with mild asthma.

Authors:  S T Holgate; H Arshad; P Stryszak; J E Harrison
Journal:  J Allergy Clin Immunol       Date:  2000-05       Impact factor: 10.793

4.  A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5'-monophosphate in asthmatic patients.

Authors:  D A Taylor; M W Jensen; V Kanabar; R Engelstätter; V W Steinijans; P J Barnes; B J O'Connor
Journal:  Am J Respir Crit Care Med       Date:  1999-07       Impact factor: 21.405

5.  Airway refractoriness to adenosine 5'-monophosphate after repeated inhalation.

Authors:  Z Daxun; P Rafferty; R Richards; S Summerell; S T Holgate
Journal:  J Allergy Clin Immunol       Date:  1989-01       Impact factor: 10.793

6.  Tachyphylaxis to repeated challenges with inhaled adenosine in asthmatic subjects.

Authors:  N Crimi; F Palermo; R Oliveri; R Polosa; C Vancheri; B Palermo; A Mistretta
Journal:  Ann Allergy       Date:  1990-08

7.  Duration of effect of single-dose inhaled fluticasone propionate on AMP-induced bronchoconstriction.

Authors:  B Luijk; R D Kempsford; A M Wright; P Zanen; J W J Lammers
Journal:  Eur Respir J       Date:  2004-04       Impact factor: 16.671

8.  Add-on therapy with montelukast or formoterol in patients with the glycine-16 beta2-receptor genotype.

Authors:  Erika J Sims; Catherine M Jackson; Brian J Lipworth
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

9.  Circadian variation in airway responsiveness to methacholine, propranolol, and AMP in atopic asthmatic subjects.

Authors:  Y Oosterhoff; G H Koëter; J G De Monchy; D S Postma
Journal:  Am Rev Respir Dis       Date:  1993-03

10.  The influence of refractoriness to adenosine 5'-monophosphate on allergen-provoked bronchoconstriction in asthma.

Authors:  G D Phillips; P K Bagga; R Djukanovic; S T Holgate
Journal:  Am Rev Respir Dis       Date:  1989-08
View more
  2 in total

1.  Pharmacodynamic Studies to Demonstrate Bioequivalence of Oral Inhalation Products.

Authors:  Leslie Hendeles; Peter T Daley-Yates; Robert Hermann; Jan De Backer; Sanjeeva Dissanayake; Stephen T Horhota
Journal:  AAPS J       Date:  2015-02-26       Impact factor: 4.009

2.  Therapeutic index of inhaled corticosteroids in asthma: A dose-response comparison on airway hyperresponsiveness and adrenal axis suppression.

Authors:  Peter Daley-Yates; Noushin Brealey; Sebin Thomas; Daren Austin; Shaila Shabbir; Tim Harrison; Dave Singh; Neil Barnes
Journal:  Br J Clin Pharmacol       Date:  2020-06-17       Impact factor: 3.716

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.